Compare Lumen Technologies Inc (LUMN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Mesoblast Limited — how do they compare? Lumen Technologies Inc trades at $6.76 (market cap $6.47B), while Mesoblast Limited trades at $16.34 (market cap $2.17B). The key difference: Lumen Technologies Inc is far larger — about 3× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| LUMN | MESO | |
|---|---|---|
Market Cap | $6.47B | $2.17B |
Sector | Media | Technology |
52-Week High | $11.83 | $20.96 |
52-Week Low | $3.70 | $12.88 |
Enterprise Value | $18.10B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $6.275, down 0.08% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $1.74B in 2025 despite beating EPS estimates in two of the last three quarters. Recent news highlights strategic acquisitions like Alkira to bolster its AI networking capabilities, while the balance sheet shows high debt levels of $17.49B long-term.
The outlook remains challenging due to persistent losses and heavy debt, though cost-cutting initiatives and a $13B contract backlog offer potential upside. Analyst consensus is cautious with a $8.25 price target, but the stock's deep value (P/S 0.52) may attract contrarians if EBITDA improves. Key risks include execution on turnaround plans and interest expense pressure.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
